What the new Canada guidance says about stopping

The pharmacy regulator in Canada has issued counselling standards for initiation of GLP-1 receptor agonist therapy, specifying what must be covered at the point of supply: device technique, expected adverse effects, what to do about a missed dose, storage, sharps disposal, and — notably — what happens if treatment stops.

The titration document sets out three permissible responses to unresolved symptoms at a given dose: hold at the current dose for a further interval, return to the previous dose, or discontinue. It declines to specify a maximum hold duration, on the stated grounds that no evidence supports one.

The evidence base for most practical questions in this field is thin, and the better guidance documents say so explicitly rather than manufacturing a recommendation grade. The Journal reports the stated evidence quality alongside the recommendation, because a strong recommendation on low-quality evidence is a different object from a strong recommendation on high-quality evidence.

Marek Doležal, analytical chemist and former QC laboratory manager, noted who the document does not reach. "None of my patients who buy online will ever see this. That population is entirely outside the guidance system."

We have asked the issuing body whether the guidance will be reviewed on a fixed cycle and what would trigger an earlier revision.